Abstract: Disclosed are compounds that inhibit proteasomic activity in cells. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly cell proliferative conditions, such as cancer and inflammatory conditions.

Abstract: An 1-amido-3-(2-hydroxyphenoxy)-2-propanol derivative represented by the following formula (1), wherein cycle A may have further 1 to 4 substituents, and said substituent means a substituent selected from the group consisting of saturated or unsaturated C1-4 alkyl group, aralkyl group in which alkyl moiety has 1 to 4 carbon atoms, aryl group, halogen atom, halogenated C1-4 alkyl group, C2-5 alkanoyl group, mono or dialkylcarbamoyl group in which alkyl moiety has 1 to 4 carbon atoms, cyano group and nitro group, and the substituents at positions 3 and 6, or at positions 4 and 5 on the cycle A are different each other. Other ring may be fused at positions 3 and 4, or at positions 5 and 6 on the cycle A to form a condensed polycyclic hydrocarbon with the cycle A. R1 is alkanoyl group or aroyl group, and R2 is hydrogen atom, alkanoyl group or aroyl group, or R1 and R2 may be combined together with the N atom to form a cyclic imido group, which is useful as an intermediate of medicines, etc.

Abstract: The synthesis and study of biological activity of a series of new molecules with potential antimicrobial activity are described. The molecules are bicyclic carbohydrates, based on furanose sugars. Their antimicrobial activity against viruses is demonstrated, next to cytostatic effects. Significantly, a high and selective activity against Cytomegalovirus was observed.

Abstract: Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction of ocular hypertension.

Abstract: Novel compounds of the formula I in which R, X and n are as defined herein, are inhibitors of tyrosine kinase and can be employed for the treatment of tumours, for neuroprotection and for protection of the stress proteins of the skin.

Abstract: The present invention relates to aminoindane derivatives having the formula I wherein X, Y, U, R1-2, R13-16 and R are as defined in the claims, or an acid addition salt thereof. The compounds of the invention posses the combined effect of serotonin reuptake inhibition and norepinephrine uptake inhibition.

Abstract: Prodrugs of formula I, their uses, their intermediates, and their method of manufacture are described: and pharmaceutically acceptable prodrugs and salts thereof.

Abstract: The present invention provides a process for preparing benzoprostacycline derivatives of formula (1), i.e. 5,6,7-trinor-4,8-inter-m-phenylene PGI2 derivatives, and vinyl tin compounds of formula (III) as starting materials for the same.

Abstract: The invention relates to novel 3-phenyl-substituted, 3-substituted 4-ketolactams and -lactones of the formula (I) in which Q, W, X, Y, A, B and G are as defined in the disclosure, to processes and intermediates for their preparation and to their use as pesticides and herbicides.

Abstract: The present invention provides novel fluorine-containing copolymers which comprise at least one fluorinated olefin, at least one polycyclic ethylenically unsaturated monomer with a fused 4-membered heterocyclic ring and, optionally, other components. The copolymers are useful for photoimaging compositions and, in particular, photoresist compositions (positive-working and/or negative-working) for imaging in the production of semiconductor devices. The copolymers are especially useful in photoresist compositions having high UV transparency (particularly at short wavelengths, e.g., 157 nm) which are useful as base resins in resists and potentially in many other applications.

Abstract: Five-membered heteroaromatic keratin dyeing compounds with one, two, or three heteroatoms. This invention further relates to a composition for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and one or more 5-membered heteroaromatic keratin dyeing compounds with one, tow, or three heteroatoms. This invention further relates to a method for oxidative dyeing of keratin fibers, comprising applying such compositions in the presence of an oxidizing agent, for a period sufficient to develop the desired coloration.

Abstract: Fungicidal compounds of the general formula (1) wherein X, Y, Z, R1, R2, R3, R4 and R5 have the definitions given in claim 1

Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1, R2, R3, n, X and Y are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The present invention further provides compounds capable of inhibiting histone deacetylatase activity and methods for treating disorders regulated by histone deacetylase activity (e.g., cancer and protozoal infections) comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof. The present invention additionally provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p. The present invention also provides methods for preparing compounds of the invention.

Abstract: Disclosed herein is a dye composition for dyeing human keratin fibers, such as the hair, comprising a direct polycationic dye of formula (I) below: Col-Z-Col??(I) in which Col, which may be identical or different, is a noncationic dye chosen from azo dyes, methine dyes, azomethine dyes, phenothiazine dyes, triarylmethene dyes, xanthene dyes, phenanthridine dyes, and phthalocyanin dyes; and Z is chosen from linear and branched, saturated and unsaturated C1-C20 hydrocarbon-based groups comprising at least one nitrogen atom and bearing at least two cationic charges, and also to processes for dyeing human keratin fiber using said composition, to the use of the dyes of formula (I) as direct dyes, and to multi-compartment devices.

Abstract: Purification of poly-amino acid-tagged recombinant proteins has been improved by the use of a carboxymethylated aspartate ligand complexed with a third-block transition metal having an oxidation state of 2+ and a coordination number of 6. A method for synthesizing the metal ion-CM-Asp complex is also described. Further, the metal ion-CM-Asp complex can be used for screening protein function.

Abstract: Disclosed herein is a dye composition for dyeing human keratin fibers, such as the hair, comprising a direct polycationic dye of formula (I) below: Col-Z-Col??(I) in which Col, which may be identical or different, is a monocationic dye chosen from azo dyes, methine dyes, azomethine dyes, and phenothiazine dyes; and Z is chosen from linear and branched, saturated and unsaturated C1–C20 hydrocarbon-based groups comprising at least one nitrogen atom and bearing at least two cationic charges, and also to processes for dyeing human keratin fibers using said composition, to the use of the dyes of formula (I) as direct dyes, and to multi-compartment devices.

Abstract: A dye composition for dyeing human keratin fibers, such as hair, comprising at least one direct tricationic dye of formula (I) below: Col—Z—Col ??(I) wherein: Col, which may be identical or different, is a monocationic dye chosen from azo dyes, cyanomethine dyes and phenothiazine dyes and Z is chosen from linear and branched, saturated and unsaturated C1–C20 hydrocarbon-based groups comprising at least one nitrogen atom and bearing a cationic charge. Also processes for dyeing human keratin fibers using the dye composition, to the use of the at least one direct tricationic dye of formula (I) as direct dyes, and to multi-compartment devices.

Abstract: The compound according to the formula set forth below and the use of the compound in creating fragrances, and scents in items such as perfumes, colognes and personal care products is disclosed.

Abstract: This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a taxane, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to intitiate receptor activities which results in tumor growth inhibition, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use.

Abstract: 1,3-Dihydroxybenzene derivatives of general formula (I) or (Ia) or physiologically tolerated, water-soluble salts thereof wherein R?1 denotes a substituted pyridyl group, a pyrimidyl group, a group of formula (IIa) or (IIIa) and the dyeing agents for keratin fibers containing these compounds.

Abstract: Polyphenol-containing compositions, for example procyanidins and derivatives thereof, and their use for treating hypertension are disclosed. Compositions may be used for human and veterinary use, and may be, for example, in a form of a food, a dietary supplement or a pharmaceutical.

Abstract: The invention provides cannabinol derivatives and pharmaceutical preparations thereof.

Abstract: Disclosed are novel diaminothiazoles that are selective inhibitors of Cdk4. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds as well as intermediates useful in the preparation of the compounds.

Abstract: A dye composition for dyeing human keratin fibres, such as hair, comprising at least one dissymmetrical polycationic direct dye of formula (I) below: Col1-Z-Col2??(I) wherein: Col1 and Col2, which differ in structure, are chosen from tazo dyes, methine dyes, azomethine dyes, phenothiazine dyes, triarylmethane dyes, xanthene dyes, phenanthridine dyes and phthalocyanin dyes and Z is chosen from linear and branched, saturated, unsaturated and cyclic C1–C20 hydrocarbon-based groups comprising at least one nitrogen atom and bearing at least one cationic charge; and also to processes for dyeing human keratin fibres using the composition, to the use of the at least one dissymmetrical polycationic direct dye of formula (I) as direct dyes, and to multi-compartment devices.

Abstract: The present invention discloses an antineoplastic sterile lyophilized powder of lentinan and the process of preparation thereof. The lyophilized powder of lentinan is essentially consisted of 0.50–1.40 parts of lentinan and 50–140 parts of excipient for lyophilization, based on weight. It has good stability. It has improved safety as it does not contain dextran which may cause allergic side effect.

Abstract: Disclosed and claimed are cocoa extracts, compounds, combinations thereof and compositions containing the same, such as polyphenols or procyanidins, methods for preparing such extracts, compounds and compositions, as well as uses for them, especially a polymeric compound of the formula An, wherein A is a monomer of the formula: wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units; R is 3-(?)—OH, 3-(?)—OH, 3-(?)—O-sugar, or 3-(?)—O-sugar; bonding between adjacent monomers takes place at positions 4, 6 or 8; a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry; X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto (the bonding of the additional monomeric unit adjacent to the terminal monomeric unit) is at position 4 and

Abstract: The present invention provides a lipid-rich plaque regressing agent comprising a compound represented by Formula: in which ring A is a cyclic hydrocarbon or the like; ring B is a heterocyclic ring or the like; each of X and Y is —NR1— (in which R1 is a hydrocarbon or the like); D is a C1-3 alkylene group or the like; E is —NH— or the like; G is a bond or the like; and Ar is an aryl or the like; D may be taken together with a constituent atom of the ring B to form a ring, and R4 may be taken together with a constituent atom of the ring B to form a ring.

Abstract: The present application describes novel spiro-cyclic ?-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), and/or aggrecanase inhibitors.

Abstract: The invention provides dicarboxylic acid-substituted heteroaryl derivatives of the formula G1-(C(R1)R2)n-Q1-B-Q2-(C(R3)R4)m-G2??I or a pharmaceutically acceptable salt thereof, wherein G1, G2, R1, R2, R3, R4, n, m, Q1, Q2, and B are as defined in the specification. The invention compounds are inhibitors of matrix metalloproteinase enzymes, including MMP-13. This invention also provides pharmaceutical compositions and methods of treating diseases mediated by MMP-13, including arthritis, asthma, heart disease, atherosclerosis, and osteoporosis, or a pharmaceutically acceptable salt thereof.

Abstract: The new N-heteroarylmethyl-p-phenylenediamine derivatives have the general formula (I), Oxidation hair dyeing agents are described based on a combination of developing and coupling substance, which contain at least one N-heteroarylmethyl-phenylenediamine derivative of the formula (I), or a physiologically tolerated salt thereof.

Abstract: This invention relates to epoxidized acetals and thioacetals, episulfidized acetals and thioacetals, thermosetting resin compositions based on such epoxidized acetals and thioacetals, episulfidized acetals and thioacetals, reaction products of which are controllably degradable when subjected to appropriate conditions.

Abstract: The present invention provides compounds, compositions and methods for the inhibition or treatment of conditions or disorders modulated by the STAT transcription factors, particularly STAT4 and STAT6. Additionally, the compounds are useful for the diagnosis of conditions dependent on STAT signaling.

Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.

Abstract: Compounds of the general formula (I) are described: wherein each of R1, R2, R3, R4, R5 and R6 independently represents a substituent selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, and isopropyl; an wherein x represents either 0 or 1. The compounds are useful as fragrances and as added components in fragrance blends. Methods of improving the harmony, emanation, naturalness an staying power of other fragrance ingredients by the addition of such compounds are also described.

Abstract: The present invention provides hydroxypyridinone and hydroxypyrimidone chelating agents. Also provides are Gd(III) complexes of these agents, which are useful as contrast enhancing agents for magnetic resonance imaging. The invention also provides methods of preparing the compounds of the invention, as well as methods of using the compounds in magnetic resonance imaging applications.

Abstract: The rate of aminolysis of butyrolactones is predictably adjusted by attaching a substituent having a known field effect value (F) to the alpha position before reacting the substituted buytrolactone with an amine. The aminolysis product is a gamma-hydroxy amide. The resulting materials are useful as the cross-linking agents in a variety of coatings and coatings processes.

Abstract: The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.

Abstract: A liquid crystalline compound represented by Formula (1c′): wherein R1 and R2, rings A1, A2, A3, A4 and A5, Z1, Z2, Z3 and Z4, Y1, Y2, Y3 and Y4, and k, l, m and n are as defined in the specification. Also provided is a liquid crystal composition containing at least one of these liquid crystalline compounds.

Abstract: Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.

Abstract: Colorants for keratin fibers containing 1,3-diamino-4-heteroarylbenzene derivatives of general formula (I) or the physiologically tolerated salts thereof as well as novel 1,3-diamino-4-heteroarylbenzene derivatives.

Abstract: Photoiniferters for controlled radical polymerizations are described. The photoiniferters have an azlactone or ring-opened azlactone moiety to provide telechelic (co)polymers.

Abstract: Tertiary diamines having formula (I), wherein Ar is an aromatic group selected from: formula (n), where n=1 to 3; formula (m), where m=1 to 3; formula (p), where p=1 to 3, R1 is a group selected from alkyl, alkenyl, cycloalkyl, cycloalkenyl, carbocyclic aryl optionally substituted by at least one group selected from halo, alkyl, cyano, nitro and cycloalkyl and an aromatic heterocyclic group optionally substituted by at least one group selected from halo, cyano, nitro, alkyl, cycloalkyl and aryl optionally substituted by at least one halo group; R2 is a fused bicyclic or tricyclic aromatic heterocyclic group selected from formula (A) and formula (B), which heterocyclic group may, optionally, be substituted by at least one group selected from halo, cyano, nitro, alkyl, cycloalkyl and aryl optionally substituted by at least one halo and wherein Q is O, S or N—R5 where R5 is H, alkyl, cycloalkyl or aryl optionally substituted by at least one group selected from halo, alkyl, cyano or nit

Abstract: There are described novel rhodol dye compounds The dye compounds exhibit a first color when in the crystalline form and a second color, different from the first color, when in the liquid, amorphous form.

Abstract: Chain transfer agents for controlled radical polymerizations (RAFT) are described. The chain transfer agents have an azlactone or ring-opened azlactone moiety to provide telechelic (co)polymers.

Abstract: Photoiniferters for controlled radical polymerizations are described. The photoiniferters have an azlactone or ring-opened azlactone moiety to provide telechelic (co)polymers.

Abstract: The invention relates to insecticidal mixtures comprising compounds of the formula (I) in which X′, Y′, Z′, n, G′, A′ and B′ are as defined above and agonists and/or antagonists of nicotinic acetylcholine receptors, for protecting plants against attack by pests.

Abstract: The invention relates to the use of ascorbic acid analogs as buffering reagents and chelating agents for the preparation of metalloradiopharmaceuticals. Also, invention relates to the use of ascorbic acid as a buffering reagent, a chelating agent, and a stabilizer for the preparation and stabilization of radiopharmaceuticals and processes for making and using the same.

Abstract: An electroluminescent element is disclosed, comprising an electroluminescent material and a fluorescent substance emitting light having an emission maximum at the wavelength different from that of light emitted from the electroluminescent material upon absorption of the light emitted from the electroluminescent material. A color conversion filter is also disclosed, comprising a fluorescent substance emitting light having an emission maximum at the wavelengths of 400 to 700 nm upon absorption of the light emitted from the electroluminescent material.

Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2 , R3 and R4 are as defined herein.

Abstract: The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.